Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab [Phase 2]
A Phase 2 clinical trial update notes that participants who previously enrolled in an elotuzumab study may continue receiving treatment, and…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. [Phase 2]
Phase 2 clinical trial evaluating the safety and efficacy of carfilzomib-based regimens (CCyd or CRd) followed by autologous stem cell trans…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma [Phase 4]
Clinical trial update shows a Phase 4 study to assess safety of Teclistamab in Indian participants with relapsed and refractory multiple mye…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients
An update reporting on the analysis of effectiveness and safety of teclistamab in patients with relapsed and refractory multiple myeloma in …
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) [Phase 1]
The document reports the completed Phase 1 study evaluating escalating doses of the investigational drug forimtamig in relapsed or refractor…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma [Phase 1]
A Phase 1 study is evaluating the combination of mezigdomide and talquetamab in relapsed and refractory multiple myeloma and is currently re…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Connect® MM- The Multiple Myeloma Disease Registry
The Connect MM registry trial for multiple myeloma sponsored by Celgene has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]
Teclistamab is being studied in a Phase 2 trial for relapsed or refractory multiple myeloma. The study status is active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]
Phase 3 study evaluating teclistamab in combination with daratumumab subcutaneously versus DPd or DVd regimens in relapsed or refractory mul…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) [Phase 2]
Phase 2 clinical trial update evaluating Ulixertinib (BVD-523) in cancers with targeted genetic alterations under MATCH Subprotocol Z1L; the…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 dose-escalation study evaluating talquetamab in participants with relapsed or refractory multiple myeloma; the trial status is activ…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]
This document notes an ongoing Phase 1 clinical trial evaluating JNJ-87562761 in participants with relapsed or refractory multiple myeloma. …
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) [Phase 2]
This clinical trial update reports a Phase 2 MATCH subprotocol (H) testing trametinib and dabrafenib for cancers with BRAF genetic alteratio…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma [Phase 1]
This clinical trial update describes a Phase 1 study evaluating teclistamab in combination with other anticancer therapies for multiple myel…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) [Phase 1]
This update reports results from a Phase 1 study evaluating subcutaneous TAK-079 added to standard-of-care regimens in adults with newly dia…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy [Phase 3]
Phase 3 study comparing Daratumumab-VELCADE-Lenalidomide-Dexamethasone (D-VRd) vs VELCADE-Lenalidomide-Dexamethasone (VRd) in untreated mult…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction [Phase 2]
A Phase 2 study evaluating frontline induction with carfilzomib, lenalidomide, and dexamethasone in multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy [Phase 3]
This Phase 3 trial compares D-VRd (daratumumab, bortezomib, lenalidomide, dexamethasone) with VRd in untreated multiple myeloma patients not…
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating daratumumab in combination with dexamethasone for resistant or refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma [Phase 2]
Completed Phase 2 study evaluating weekly carfilzomib with melphalan and prednisone in untreated elderly patients with symptomatic multiple …
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma [Phase 1]
A Phase 1 clinical trial is evaluating mezigdomide (CC-92480) in relapsed multiple myeloma patients who have previously received idecabtagen…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years [Phase 3]
This Phase 3 trial compares conventional-dose lenalidomide, bortezomib, and dexamethasone (RVD) against high-dose therapy with autologous st…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation [Phase 2]
This document reports the completion of a Phase 2 clinical trial evaluating PD-1 blockade in conjunction with dendritic cell/myeloma vaccine…
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Maintenance Therapy Using Lenalidomide in Myeloma [Phase 3]
Phase 3 clinical trial evaluating maintenance therapy with lenalidomide in multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia [Phase 2]
Phase 2 clinical trial evaluating IL-15-Armored CAR-T therapy in relapsed or refractory multiple myeloma and plasma cell leukemia; currently…